Transcript 7 Mullins

Karen Mullins, D.O.
University of Tennessee
Knoxville Neurology Clinic
Lecture Objectives
 Describe clinical presentations of Lewy Body and
Parkinson’s Associated Dementia(PAD)
 Describe pathophysiological mechanisms associated
with Lewy Body Dementia (LBDD) and PAD
 Review both pharmacologic and nonpharmacologic
treatments for LBDD and PAD
Clinical Presentation Of LBD
 Fluctuations in cognitive function
 Varying levels of alertness and attention
 Excessive daytime drowsiness or daytime sleep >2
hours
 Episodes of staring off into space
 Episodes of disorganized speech
Clinical Presentation Of LBD
 Visual hallucinations
 Delusions
 REM sleep behavior disorder
 Impaired excecutive function, visuospatial function
(Stroop, digit span backwards)
Clinical Presentation of LBD
 Parkinsonism
 Appears early in course of disease
 May not be enough to meet full criteria for PD
 Less frequent rest tremor
 May see myoclonus
 Orthostatic hypotension
Clinical Presentation LBD
 Capgras syndrome: delusion that people in the
environment are not themselves but actually doubles
 Also see passive personality traits- decreased
emotional responsivity, lack of interest in hobbies,
increasing apathy , purposeless hyperactivity
Diagnostic Criteria
Dementia with Lewy Bodies (DLB)
 Consensus diagnostic criteria for DLB were first established in
1996
 Dementia accompanied by ≥ 1 of three core symptoms

Fluctuating cognition, visual hallucinations, and motor
parkinsonism
 Criteria were expanded in 2005
 Neuroleptic sensitivity and RBD
 Specific imaging findings on dopamine SPECT imaging or MIBG
cardiac scintigraphy
 Dementia with progressive cognitive deficits that result in social
and occupational dysfunction must be present for either
probable or possible DLB
Kurtz AL et al., Curr Treat Opt Neuro, 2011;13:242254.
PD Dementia
 Typically dementia occurs later in disease
 Must meet criteria for PD first
 Tremor
 Rigidity
 Akinesia/bradykinesia
 Postural instability
Manifestations at PD Onset
 Tremor at rest
 Bradykinesia
 Rigidity
 Micrographia
 Hypophonia
 Masked face
 Stooped, shuffling gait
 Slowing of activities of daily living
 Decreased arm swing when walking
Barbosa et al. Psychiatr Clin North Am. 1997;20:769-90.
Playfer. Postgrad Med. 1997;73:257-64.
Early Deficits in PD
Fronto-striatal Syndrome
 Cognitive flexibility
 Planning
 Working memory
 Learning
 Prodrome to dementia?
Kehagia AA et al., Lancet Neurol, 2010;9:1200-1213.
Mild Cognitive Impairment in PD
 20% - 57% of patients are affected in 3-5 years of PD diagnosis
 PD as a fronto-striatal syndrome
 Deficits clear when patients need to act based on internal rather
than external cues
 DA Dependent
 Flexibility, switching between known tasks, working memory
 DA Independent
 Mental rotation, verbal memory
Kehagia AA et al., Lancet Neurol, 2010;9:1200-1213.
PD Dementia
Diagnostic Criteria
 PDD associated with mortality
 Longitudinal estimates of its cumulative prevalence
are 75% to 90%
 PD patients are three to five times more likely to
develop dementia compared with healthy individuals
 Closely related to dementia with Lewy bodies
 Both are distinguishable from AD
 Lewy bodies, plaques, and vascular changes are present
in both
 Different temporal profiles
Kehagia AA et al., Lancet Neurol, 2010;9:1200-1213.
Diagnostic Criteria for PDD





Diagnosis of PD by the Queen Square brain bank criteria
PD precedes dementia onset
MMSE score of <26
Severe cognitive dysfunction that interferes with daily living
Impairment on at least tow





Three-word recall (MMSE)
Overlapping pentagons (MMSE)
Months reverse or sevens backward (MMSE)
Lexical fluency
Clock drawing
 Absence of major depression, delirium, or other abnormalities
that obscure diagnosis
Neuropsychological Deficits in PDD
 Executive

Wisconsin card sorting test; Stroop performance; Odd-ManOut, verbal fluency
 Working Memory

Digit and spatial span
 Memory

Free and cued recall, auditory verbal learning
 Visuospatial Abilities

Clock drawing, Benton line orientation, face recognition,
fragmented letters
Key Points : LBDD vs PAD
 LBDD presents with dementia early on in the disease
 LBDD are more likely to have hallucinations, delusions
early on in disease course
 LBDD have fewer Parkinsonian symptoms
 PAD must meet criteria for PD, dementia occurs later
in disease course
Pathophysiology LBDD
 Lewy Bodies- eosinophilic inclusion bodies
 Present in brainstem and cerebral cortex
 See changes in basal ganglia>>reduction in # of
cholinergic projections to thalamic reticular nucleus>>
reduction in cholinergic neurotransmission
 Specific to LBD: correlation between hallucinations,
staring spells and decreased cholinergic function
Pathophysiology LBDD
 Nagahama et al found SPECT scan studies of 145 DLB
patients revealed:
 Visual hallucinations- hypoperfusion of parietal-
occipital association cortices
 Misidentifications- hypoperfusion of the limbicparalimbic structures
 Delusions- hypoperfusion of the frontal cortices
Pathophysiology of PAD
 See loss of pedunculopontine cholinergic
neurons>>loss of dopamine, norepinephrine or
acetylcholine neurotransmitters
 May see inability of ACH transporting ions to bind to
receptors
 Als0 see presence of abnormal tau genes
Imaging in PD Dementia
Amyloid Imaging
 Cortical amyloid deposition is significantly increased
in DLB

Amyloid burden in PDD and PD-ND similar
 PDD subjects shown to have significantly decreased
PiB binding compared to AD or DLB with similar
dementia severity
 Occipital cortex


Severely compromised in DLB, PDD and PD-ND
Relative sparing in AD
Silbert LC et al., Brain Path, 2010;20:646-653.
Clinicopathologic Spectrum of
Dementia
Kurtz AL et al., Curr Treat Opt Neuro, 2011;13:242254.
Cognitive Impairment in PD
Cholinesterase Inhibitors
 Studied in DLB and PDD
 Provide benefit in treating cognitive and
neuropsychiatric symptoms
 Types:
 Rivastigmine approved in 2006
 Donepezil
 Galantamine
Kurtz AL et al., Curr Treat Opt Neuro, 2011;13:242254.
Cognitive Impairment in PD
Treatment Strategies
 Rivastigmine
 Dual acetylcholinesterase and
butyrylcholinesterase inhibition
 Improved apathy, anxiety, delusions nad
hallucinations in DLB patients
 Improved ADL in PDD relative to baseline
 Only stabilize AD patients
Kehagia AA et al., Lancet Neurol, 2010;9:1200-1213.
Cognitive Impairment in PD
Treatment Strategies
 Donepezil
 Acetylcholinesterase inhibition
 Tested in smaller studies
 Improve cognition as measured by MMSE
 Did not exacerbate parkinsonism
Kehagia AA et al., Lancet Neurol, 2010;9:1200-1213.
Cognitive Impairment in PD
Treatment Strategies
 Memantine
 Originally tested as a PD treatment
 Glutamatergic compound
 Non-competitive antagonist of
nicotinic acetylcholine receptors
 2009 test in PDD and DLB


Improved MMSE and global change
score
Ameliorated cognition in PDD
 May have differential therapeutic
responsivity
Kehagia AA et al., Lancet Neurol, 2010;9:1200-1213.
Mild Cognitive Impairment in PD
Atomoxetine
 Norepinephrine reuptake inhibitor
 Recent open-label study
 Improvements in clinicians global impression of change
and executive function
 AEs included gastrointestinal disturbance
 One patient exhibited hypermania
 Further studies are needed
Burn DJ et al., Brain Path, 2010;20:672-678.
Mild Cognitive Impairment in PD
Safinamide
 Dopaminergic and
glutamatergic properties

Undergoing evaluation in
early and late PD
 Preliminary study suggest
some benefit on executive
dysfunction in early PD
Burn DJ et al., Brain Path, 2010;20:672-678.
Cognitive Impairment in PD
Treatment
Kurtz AL et al., Curr Treat Opt Neuro, 2011;13:242254.
Treatment Options LBDD
 Acetylcholinesterase Inhibitors
 Atypical neuroleptics
 Antidepressants
 Dopaminergic agents
 Agonists
 Carbidopa/levodopa
Treatment Options LBDD
 Benzodiazepines
 Antiepileptics
 Gingko baloboa
Nonpharmacologic Options
LBDD/PAD
 No approved surgery (DBS)
 Keep routine
 Door alarms/chimes
 Geropsychiatric evaluation/home health
Nonpharmacologic Treatment
PAD/LBDD
 Exercise??
 Music therapy
 Yoga/tai chi
 Cognitive exercises
 Adequate nutrition
Disease Course PAD
 More predictable than DLBD as dementia occurs later
in disease course
 If cognitive issues are due to medication side effects
then often controllable or even reversible
 Adjust PD meds
 Exclude underlying infection
 Treat with atypical antipsychotic
PD Dementia
Visual Hallucinations
 Predict rapid cognitive deterioration and dementia




onset
Associated with cortical Lewy bodies
Temporal regions
Hippocampal atrophy associated with verbal learning
deficits in PDD patients having hallucinations
Patients with visual hallucinations also have frontal
hypermetabolism and orbitofrontal atrophy that
correlates with visual memory deficits
Kehagia AA et al., Lancet Neurol, 2010;9:1200-1213.
Disease Course in LBDD
 Disease symptoms fluctuate
 Harder to control
 More sensitive to medications
 As dementia occurs earlier on in illness, pts often
require assistive care earlier
Caregiver Support
 Local support groups
 Websites:
 wemove.org
 pda.org
 lbda.org
 clincialtrials.gov
 Home physical therapy, nursing etc.
 Strong social support group
Defining Characteristics
Kurtz AL et al., Curr Treat Opt Neuro, 2011;13:242254.
Take Home Points
 Both LBDD and PAD patients should be on an
acetylcholinesterase inhibitor early on- TREAT EARLY!
 Providing the caregiver with support is essential
 Further research is needed to identify biomarkers to
distinguish PAD from DLBD
 Earlier diagnosis of PD may delay onset of PAD